XOMA Royalty (XOMA) Stock Analysis & Winston Score

XOMA Royalty Corp. is a biotechnology royalty company. Instead of making drugs itself, it buys the rights to receive future royalty payments from other companies' drug programs. When those drugs get approved and sold, XOMA collects a percentage of the sales. Its "customers" are really the pharmaceutical and biotech companies whose drug royalties XOMA has purchased. XOMA makes money by collecting royalty and milestone payments tied to drug approvals and sales — it does not manufacture or sell drugs directly. The company operates primarily in the United States and has built a portfolio of royalty interests across dozens of drug programs at various stages of development. Its high gross margin reflects the low-cost nature of royalty collection, but its growth depends heavily on whether the drugs in its portfolio successfully win regulatory approval and reach commercial scale — a risk that remains largely outside XOMA's control.